Blog
RSS FeedPosted by Michael Wonder on 24 Oct 2022
Saskatchewan becomes sixth Canadian province to implement a biosimilar switching policy
21 October 2022 - Saskatchewan joined five provinces and one territory in implementing a biosimilar switching policy, allowing for reference ...
Posted by Michael Wonder on 18 May 2021
Sandoz Canada congratulates the Quebec government on implementing a shift towards biosimilars
18 May 2021 - The shift announced by Quebec will follow a similar approach to policies introduced in British Columbia, Alberta ...
Posted by Michael Wonder on 06 May 2021
Alberta, Canada, begins mandating switches from originator to biosimilar Humira
6 May 2021 - Alberta, Canada becomes the latest province to begin switching patients from originator adalimumab (Humira) to biosimilar ...
Posted by Michael Wonder on 05 Nov 2020
Alberta, Canada sees early success from switching patients to biosimilars
5 November 2020 - Following the launch of its Biosimilars Initiative in December 2019, Alberta, Canada, has succeeded in switching 16% ...
Posted by Michael Wonder on 27 Oct 2020
Sales of cancer medicines in Canada nearly tripled over the past decade
27 October 2020 - Today, the PMPRB, under the National Prescription Drug Utilization Information System (NPDUIS) initiative, released a chartbook ...
Posted by Michael Wonder on 15 Jun 2020
Rising costs explain why Canada is switching to biosimilars
15 June 2020 - Following in the footsteps of British Columbia, other Canadian provinces are working to implement their own biosimilars ...
Posted by Michael Wonder on 13 Dec 2019
Alberta changes coverage of biologic drugs for people with Crohn's, diabetes, arthritis
12 December 2019 - The provincial government says will free up hundreds of millions of dollars in health funding during the ...
Posted by Michael Wonder on 12 Dec 2019
Canadian study shows substantial savings possible with use of biosimilar filgrastim
12 December 2019 - During this week’s annual meeting of American Society of Hematology, researchers from Canada reported that using biosimilar ...
Posted by Michael Wonder on 12 Dec 2019
Alberta will force patients to switch from biologics to cheaper biosimilar medications
12 December 2019 - Alberta will force 26,000 patients on government-sponsored drug plans to switch from expensive drugs that are known ...
Posted by Michael Wonder on 18 Nov 2019
Biosimilars make progress in the Canadian market, but stakeholders see more work ahead
18 November 2019 - While much attention over the past few weeks has been on the US biosimilars market, with its ...
Posted by Michael Wonder on 10 Sep 2019
Erosion of physician and patient treatment choice continues - Alliance for Safe Biologic Medicines raises concerns for patients as British Columbia expands biologics forced switching policy
10 September 2019 - On 5 September, the Government of British Columbia announced that it would be forcibly switching 1,700 patients ...
Posted by Michael Wonder on 24 Jun 2019
Forcing patients to switch to biosimilars puts them in uncharted waters
23 June 2019 - On May 27, the B.C. government announced a policy that will forcibly switch thousands of patients, ...
Posted by Michael Wonder on 18 Jun 2019
Advisory Council supports biosimilars in call for universal public drug coverage in Canada
17 June 2019 - A Canadian advisory council is recommending the use of biosimilars in a final report that lays ...
Posted by Michael Wonder on 06 Jun 2019
Patients, physicians raise concerns with BC biosimilar non-medical switching policy
6 June 2019 - On 27 May, the Government of British Columbia announced a policy that will forcibly switch thousands ...
Posted by Michael Wonder on 21 Jan 2019
Canadian payer reports a successful switch to biosimilars
21 January 2019 - In 2018, Green Shield Canada launched its pilot Biosimilar Transition Program, through 3 plan sponsors, under which ...